These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34980038)

  • 1. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
    Rosenberg AJ; Izumchenko E; Pearson A; Gooi Z; Blair E; Karrison T; Juloori A; Ginat D; Cipriani N; Lingen M; Sloane H; Edelstein DL; Keyser K; Fredebohm J; Holtrup F; Jones FS; Haraf D; Agrawal N; Vokes EE
    BMC Cancer; 2022 Jan; 22(1):17. PubMed ID: 34980038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
    Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
    Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
    Rosenberg AJ; Agrawal N; Juloori A; Cursio J; Gooi Z; Blair E; Chin J; Ginat D; Pasternak-Wise O; Hasina R; Starus A; Jones FS; Izumchenko E; MacCracken E; Wolk R; Cipriani N; Lingen MW; Pearson AT; Seiwert TY; Haraf DJ; Vokes EE
    JAMA Oncol; 2024 Jul; 10(7):923-931. PubMed ID: 38842838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
    Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
    Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status.
    Kim MJ; Ki MS; Kim K; Shim HJ; Hwang JE; Bae WK; Chung IJ; Lee DH; Lee JK; Yoon TM; Lim SC; Chung WK; Jeong JU; Lim HS; Choi YD; Cho SH
    BMC Cancer; 2014 Nov; 14():824. PubMed ID: 25380690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Rosenberg AJ; Agrawal N; Pearson A; Gooi Z; Blair E; Cursio J; Juloori A; Ginat D; Howard A; Chin J; Kochanny S; Foster C; Cipriani N; Lingen M; Izumchenko E; Seiwert TY; Haraf D; Vokes EE
    Oral Oncol; 2021 Nov; 122():105566. PubMed ID: 34662771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma.
    Reder H; Taferner VF; Wittekindt C; Bräuninger A; Speel EM; Gattenlöhner S; Wolf G; Klussmann JP; Wuerdemann N; Wagner S
    J Mol Diagn; 2020 Nov; 22(11):1333-1343. PubMed ID: 32822851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of human papillomavirus cell-free DNA from low-volume blood plasma samples by digital PCR.
    Rosing F; Meier M; Schroeder L; Laban S; Hoffmann T; Kaufmann A; Siefer O; Wuerdemann N; Klußmann JP; Rieckmann T; Alt Y; Faden DL; Waterboer T; Höfler D
    Microbiol Spectr; 2024 Jul; 12(7):e0002424. PubMed ID: 38829114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer.
    Hanna GJ; Lau CJ; Mahmood U; Supplee JG; Mogili AR; Haddad RI; Jänne PA; Paweletz CP
    Oral Oncol; 2019 Aug; 95():120-126. PubMed ID: 31345379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer.
    Hanna GJ; Supplee JG; Kuang Y; Mahmood U; Lau CJ; Haddad RI; Jänne PA; Paweletz CP
    Ann Oncol; 2018 Sep; 29(9):1980-1986. PubMed ID: 30010779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.
    Nichols AC; Lang P; Prisman E; Berthelet E; Tran E; Hamilton S; Wu J; Fung K; de Almeida JR; Bayley A; Goldstein DP; Eskander A; Husain Z; Bahig H; Christopoulous A; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Mendez A; Winquist E; Read N; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Corsten M; Rajaraman M; Johnson-Obaseki S; Eapen L; Odell M; Chandarana S; Banerjee R; Dort J; Matthews TW; Hart R; Kerr P; Dowthwaite S; Gupta M; Zhang H; Wright J; Parker C; Wehrli B; Kwan K; Theurer J; Palma DA
    BMC Cancer; 2020 Feb; 20(1):125. PubMed ID: 32059705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
    Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
    Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
    Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
    J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Free Human Papillomavirus-DNA for Monitoring Treatment Response of Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
    Campo F; Zocchi J; Moretto S; Mazzola F; Petruzzi G; Donà MG; Benevolo M; Iocca O; De Virgilio A; Pichi B; Manciocco V; Pellini R
    Laryngoscope; 2022 Mar; 132(3):560-568. PubMed ID: 34236084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
    Marur S; Li S; Cmelak AJ; Gillison ML; Zhao WJ; Ferris RL; Westra WH; Gilbert J; Bauman JE; Wagner LI; Trevarthen DR; Balkrishna J; Murphy BA; Agrawal N; Colevas AD; Chung CH; Burtness B
    J Clin Oncol; 2017 Feb; 35(5):490-497. PubMed ID: 28029303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
    Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
    J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
    Haddad RI; Massarelli E; Lee JJ; Lin HY; Hutcheson K; Lewis J; Garden AS; Blumenschein GR; William WN; Pharaon RR; Tishler RB; Glisson BS; Pickering C; Gold KA; Johnson FM; Rabinowits G; Ginsberg LE; Williams MD; Myers J; Kies MS; Papadimitrakopoulou V
    Ann Oncol; 2019 Mar; 30(3):471-477. PubMed ID: 30596812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
    Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
    Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.
    Dunn LA; Fury MG; Sherman EJ; Ho AA; Katabi N; Haque SS; Pfister DG
    Head Neck; 2018 Feb; 40(2):233-241. PubMed ID: 28963790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.